EHS
EHS

On the role of the immunoproteasome in transplant rejection.

Related Articles

On the role of the immunoproteasome in transplant rejection.

Immunogenetics. 2018 Sep 15;:

Authors: Basler M, Li J, Groettrup M

Abstract
The immunoproteasome is expressed in cells of hematopoietic origin and is induced during inflammation by IFN-γ. Targeting the immunoproteasome with selective inhibitors has been shown to be therapeutically effective in pre-clinical models for autoimmune diseases, colitis-associated cancer formation, and transplantation. Immunoproteasome inhibition prevents activation and proliferation of lymphocytes, lowers MHC class I cell surface expression, reduces the expression of cytokines of activated immune cells, and curtails  T helper 1 and 17 cell differentiation. This might explain the in vivo efficacy of immunoproteasome inhibition in different pre-clinical disease models for autoimmunity, cancer, and transplantation. In this review, we summarize the effect of immunoproteasome inhibition in different animal models for transplantation.

PMID: 30220008 [PubMed – as supplied by publisher]

Source link

EHS
Back to top button